124 related articles for article (PubMed ID: 10713660)
1. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385).
Leaf AN; Wolf BC; Kirkwood JM; Haselow RE
Med Oncol; 2000 Feb; 17(1):47-51. PubMed ID: 10713660
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
[TBL] [Abstract][Full Text] [Related]
3. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
Olver IN; Stephenson J; Schulze D
Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
[TBL] [Abstract][Full Text] [Related]
5. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G
Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gedlicka C; Kornfehl J; Turhani D; Burian M; Formanek M
Cancer Invest; 2006; 24(3):242-5. PubMed ID: 16809151
[TBL] [Abstract][Full Text] [Related]
7. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.
Short SC; Suovuori A; Cook G; Vivian G; Harmer C
Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):569-74. PubMed ID: 15630851
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
Needle MN; Molloy PT; Geyer JR; Herman-Liu A; Belasco JB; Goldwein JW; Sutton L; Phillips PC
Med Pediatr Oncol; 1997 Jul; 29(1):28-32. PubMed ID: 9142202
[TBL] [Abstract][Full Text] [Related]
10. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.
Saphner T; Weller EA; Tormey DC; Pandya KJ; Falkson CI; Stewart J; Robert NJ
Am J Clin Oncol; 2000 Jun; 23(3):258-62. PubMed ID: 10857889
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral etoposide for patients with advanced breast cancer.
Atienza DM; Vogel CL; Trock B; Swain SM
Cancer; 1995 Dec; 76(12):2485-90. PubMed ID: 8625074
[TBL] [Abstract][Full Text] [Related]
12. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
13. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
Fulton D; Urtasun R; Forsyth P
J Neurooncol; 1996 Feb; 27(2):149-55. PubMed ID: 8699237
[TBL] [Abstract][Full Text] [Related]
16. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
17. Etoposide for recurrent spinal cord ependymoma.
Chamberlain MC
Neurology; 2002 Apr; 58(8):1310-1. PubMed ID: 11971113
[No Abstract] [Full Text] [Related]
18. Long-lasting complete remission after prolonged administration of etoposide in a child with a second recurrence of alveolar rhabdomyosarcoma.
Schiavetti A; Castello MA; Gauthier F; Oberlin O
Med Pediatr Oncol; 1997 Feb; 28(2):144-6. PubMed ID: 8986152
[TBL] [Abstract][Full Text] [Related]
19. Chronic oral VP-16 for recurrent medulloblastoma.
Chamberlain MC; Kormanik PA
Pediatr Neurol; 1997 Oct; 17(3):230-4. PubMed ID: 9390699
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
